OncoSec Medical Incorporated

OncoSec Announces Closing of $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

by

EWING, N.J. and SAN DIEGO, May 18, 2023 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and eradicate disease, today announced the closing of its previously announced registered direct offering of 1,408,384 shares of its … Read more

OncoSec Announces $1.33 Million Registered Direct Offering Priced At-The-Market Under Nasdaq Rules

by

EWING, N.J. and SAN DIEGO, May 16, 2023 /PRNewswire/ — OncoSec Medical Incorporated (NASDAQ: ONCS) (the “Company” or “OncoSec”), a clinical-stage biotechnology company developing intratumoral immunotherapies to stimulate the patient’s immune system to target cancer cells and eradicate disease, today announced that it has entered into a definitive agreement for the purchase and sale of  … Read more